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Abstract. Purpose: Carbimazole ameliorates hyperthy-
roidism but reduces radioiodine uptake and adversely
affects the outcome of simultaneous radioiodine therapy.
We explored whether withdrawal of carbimazole for 3
days can restore the outcome of radioiodine treatment
without concurrent exacerbation of hyperthyroidism. By
generating three groups with comparable radioiodine
uptake, we also investigated whether the effect of
carbimazole depends on the radioiodine uptake.
Methods: Stratified by a radioiodine uptake >30%, 227
consecutive adult patients were prospectively assigned to
radioiodine therapy (target dose 200 Gy) without, on or
3 days off carbimazole. Patients were clinically (Crooks-
Wayne score) and biochemically (T3, fT4, TSH) followed
up after 3, 6 and 12 months. Primary endpoint was
outcome 12 months after radioiodine therapy.
Results: A total of 207 patients completed follow-up (toxic
nodular goitre, n=117; Graves’ disease, n=90). The overall
success rate was 71.5%. Patients without and 3 days off
carbimazole had similar biochemical (81.4% and 83.3%,
respectively; p=0.82) and clinical outcomes [median
(range) Crooks-Wayne score 0 (0–16) and 1 (0–10),
respectively; p=0.73], which were both higher than in
patients on carbimazole [42.6%, p<0.001; Crooks-Wayne
score 3 (0–30), p<0.03]. Time to achieve cure was delayed
on carbimazole. No changes in thyroid hormone levels
occurred after 3 days’ discontinuation of carbimazole.
Logistic regression revealed that all observed cure rates
were independent of entity, sex, age, thyroid volume,
radioiodine uptake, radioiodine half-life, fT4, T3 and TSH.
Conclusion: Patients under carbimazole treatment can be
referred for radioiodine therapy after withdrawal of
carbimazole for only 3 days. Three days of carbimazole
withdrawal is long enough to restore the success of
radioiodine therapy and short enough to avoid the risk of
exacerbation of hyperthyroidism.
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Introduction
Hyperthyroid patients admitted to radioiodine therapy are
often prescribed carbimazole to accelerate the return of
euthyroidism, to ameliorate clinical symptoms and to
prevent the exacerbation of hyperthyroidism after admin-
istration of radioiodine [1, 2]. Unfortunately, patients
receiving radioiodine under simultaneous carbimazole
medication show significantly lower success rates than
patients who do not receive carbimazole [3–5]. Withdrawal
of carbimazole has the potential to overcome this
detrimental effect [6–8], but discontinuation for 5 days or
longer leads to exacerbation of hyperthyroidism [9].
Reports from prospective interventional studies on the
outcome of radioiodine treatment after a brief period of
carbimazole withdrawal, however, are limited [5, 7, 8].
The underlying mechanism of the detrimental effects of
carbimazole on the success rate of radioiodine treatment is
not fully understood. Carbimazole decreases the peroxi-
dase-catalysed synthesis of oxygen free radicals, which
mediate the cell damage produced by radioiodine [10, 11].
On the other hand, carbimazole reduces the cellular
radioiodine uptake [3, 5], which has also been thought to
decrease the success of radioiodine therapy [12, 13].
Accordingly, low success of radioiodine therapy under
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carbimazole has only been described in conjunction with
significantly lower radioiodine uptake under carbimazole
[3, 5].
Against this background, our first aim was to explore
whether 3 days of carbimazole withdrawal can fully restore
the success of radioiodine treatment without concurrent
exacerbation of hyperthyroidism. Second, we aimed to
explore whether carbimazole impairs the outcome of
radioiodine therapy independently of the radioiodine
uptake; for this purpose we generated three patient groups
(without, on and 3 days off carbimazole) with comparable
radioiodine uptake.
Materials and methods
Inclusion criteria
Patients older than 18 years with confirmed hyperthyroidism due to
Graves’ disease or toxic nodular goitre were eligible for inclusion
(Fig. 1). The diagnosis of Graves’ disease was based on suppressed
serum TSH levels (<0.25 mIU/l), morphology on ultrasound,
scintigraphic confirmation of diffuse goitre and elevated serum
TSH receptor antibodies. The diagnosis of toxic nodular goitre was
based on suppressed serum TSH levels (<0.25 mIU/l), morphology
on ultrasound and scintigraphic confirmation of thyroid nodules.
Exclusion criteria were pretreatment with antithyroid drugs other
than carbimazole, pregnancy, breast-feeding or incontinence. Radio-
iodine therapy was not performed when radioiodine uptake was
lower than 30%, as uptake below this level has been shown to
significantly decrease the success of radioiodine treatment [12]. The
population in the referral area has a negligible incidence of dietary
iodine deficiency owing to mandatory iodine supplementation of
dietary salt in Switzerland. The study was approved by the local
ethics committee (approval no. EKBB145/02), informed consent was
obtained and the endpoints were predefined.
Generation of patient groups without, on and 3 days off carbimazole
with comparable radioiodine uptake
The three groups were stratified as follows: Radioiodine uptake was
measured in all patients. Patients pretreated with carbimazole (by
their general practitioner or endocrinologists) who had radioiodine
uptake exceeding 30% were assigned to the group on carbimazole.
Thereby, radioiodine therapy was performed under simultaneous
carbimazole treatment. On the other hand, if the radioiodine uptake
was below 30%, carbimazole was discontinued for 3 days prior to
radioiodine treatment, a measure which, in our experience,
significantly increases the radioiodine uptake [14]. The third group
comprised who were not treated with carbimazole, i.e. were assigned
to receive radioiodine treatment without carbimazole.
Biochemical investigation
Thyroid function was assessed by measuring serum free T4 (RIA-
gnost FT4, CIS bio international, reference range 9.0–24.5 pmol/l),
serum T3 (RIA-gnost T3, CIS bio international, reference range 0.9–
2.5 nmol/l) and serum TSH (RIA-gnost TSH, CIS bio international,
reference range 0.25–4.0 mIU/l). Hyperthyroidism was defined as an
abnormally low serum TSH level, while hypothyroidism was defined
as a TSH level above the reference range. Subclinical hyperthyroid-
ism was defined as a serum TSH level below the normal reference
range and serum fT4 and T3 levels within the respective reference
ranges [15].
Iodine kinetics and thyroid scintigraphy
Iodine kinetics were determined as previously described [14, 16]. In
brief, thyroid uptake was measured at 2, 4, 24 and 48 h after
application of 7 MBq 123I using a previously calibrated scintillation
counter with a 3-inch sodium iodide crystal and scalar ratemeter
(Biodex Medical Systems). Measurement was performed for 2 min
with the patient positioned upright and with the anterior surface of
the neck 25 cm from the detector. Attenuation correction was done
with the detector shielded from the remainder of the body. Resulting
uptake (decay and dead time corrected) was calculated using
background radiation correction and reference standard: thyroid
uptake=(neck counts−thigh counts)/(reference counts−room counts).
The peak radioiodine uptake assessed at 2, 4, 24 or 48 h was
employed to define the radioiodine uptake for stratification and
subsequent dose calculation. Scintigraphy was performed using a
gamma camera equipped with a low-energy high-resolution parallel-
hole collimator (Basicam, Siemens, Erlangen, Germany). Each
image was acquired for 10 min. The images were interpreted using
both computer screen (256 grey scale) and film by board-certified
nuclear medicine physicians.
Thyroid ultrasound
Ultrasound was performed for determination of the thyroid volume
using a Logiq 400 MD and a Kodak Laser Imager Keypad
transducer. Volume was determined by an ellipsoid model (mass=
height × width × depth × 0.52) of each lobe and the height, width and
depth of the isthmus [17].
Radioiodine therapy
Radioiodine treatment was performed as previously described [16].
The individual activity applied was calculated according to
Marinelli’s formula [18]: Dose of 131I (MBq)=Intended dose (Gy) ×
Target volume (ml) × 25/Maximal radioiodine uptake (%) × T1/2 (h).
Intended tissue-absorbed doses of 200Gywere administered. Patients
in whom carbimazole had been withdrawn for 3 days resumed
carbimazole medication 4 days after radioiodine administration.
Thyrostatic medication was discontinued in all patients 6 weeks after
radioiodine treatment. Radioiodine therapy was accompanied by the
provision of standardised radiation protection guidelines and
information that hypothyroidism was a likely outcome of radioiodine
therapy.
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Follow-up
Patients were initially examined and followed up at 3, 6 and
12 months, by clinical assessment using the semiquantitative Crooks-
Wayne score [19]. This score includes 13 discriminating signs and
symptoms of hyperthyroidism and ranges between 0 and 31 points,
with higher values indicating more severe clinical hyperthyroidism.
Furthermore, patients were assessed by measuring serum T3, fT4 and
TSH levels at baseline and 3, 6 and 12 months after radioiodine
treatment. Successful radioiodine therapy was defined by clinical and
biochemical evidence of euthyroidism or hypothyroidism at
12 months after radioiodine treatment.
Statistical analysis
Discrete variables are expressed as counts (percentage) and contin-
uous variables as median (range), unless otherwise stated. The
endpoints were predefined. Frequency comparison was performed by
means of the chi-square test. Kruskal-Wallis one-way analysis of
variance with Dunn’s multiple post hoc test was used if more than two
groups were being compared. The statistical significance of changes
in quantitative measures over time was assessed using the signed rank
test. To test whether differences in success rates between groups
persisted when taking into account differences in patients’ baseline
characteristics across groups, we performed a logistic regression
analysis with treatment success as the binary outcome variable and
sex, age, thyroid volume, radioiodine uptake, radioiodine half-life,
fT4, T3, TSH, baseline Crooks-Wayne score and administered
radioiodine dose as covariates. Backward selection with a threshold
significance level of 0.2 was then applied to obtain a more
parsimonious model. A p value of <0.05 was considered to be
statistically significant. Data were analysed using Statistica V.6.0 for
Windows (StatSoft, Inc., Tulsa, OK, USA).
Results
Study groups without, on or 3 days off carbimazole
Of 262 consecutive patients who were transferred for
radioiodine treatment between 1 August 2002 and 1
August 2004, 259 (98.9%) were eligible for inclusion.
Thirty-two patients were excluded owing to low radioio-
dine uptake and 227 patients were prospectively assigned
to receive radioiodine treatment without, on or 3 days off
carbimazole (Fig. 1). Five patients (four females, one male;
median age 78 years, range 68–86 years) died in the first
year after radioiodine treatment without revealing clinical
signs of exacerbation of hyperthyroidism. Fifteen patients
were lost to follow-up, leaving 207 patients for final
analysis. The baseline criteria of the 20 lost patients did not
differ significantly from those of the remaining cohort (data
not shown).
Based on the study design, three groups without
(n=129; 88 toxic nodular goitre patients, 41 Graves’
disease patients), on (n= 54; 18 toxic nodular goitre
patients, 36 Graves’ disease patients) and 3 days off (n=24;
11 toxic nodular goitre patients, 13 Graves’ disease
patients) carbimazole and with comparable radioiodine
uptake values were generated (Table 1). The three groups
were also well balanced regarding sex, age, goitre volume,
radioiodine half-life, baseline Crooks-Wayne score, serum
T3 level and the percentage of patients with subclinical
259 Patients eligible
262 Hyperthyroid patients referred for radioiodine therapy 
3 Patients not eligible due to propylthiouracil medication
147 Assigned to radioiodine
therapy without carbimazole
55 Assigned to radioiodine
therapy on carbimazole
25 Assigned to radioiodine
therapy 3days off carbimazole
1 Died
0 Lost to follow-up
0 Died
1 Lost to follow-up
4 Died
14 Lost to follow-up 
129 Included in final analysis 54 Included in final analysis 24 Included in final analysis
179 Patients without carbimazole 80 Patients on carbimazole
32 Radioiodine Uptake <30% 147 Radioiodine Uptake >30% 55 Radioiodine Uptake >30% 25 Radioiodine Uptake <30%
25 Radioiodine Uptake >30%
after 3 days off carbimazole
No assignment to
radioiodine therapy
Fig. 1. Trial profile
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hyperthyroidism. As expected, patients in the group
without carbimazole had higher fT4 and lower TSH levels
than patients in the on and 3 days off carbimazole groups.
Based on Marinelli’s formula, higher radioiodine activities
were administered to patients on carbimazole to achieve
target doses comparable to those in patients without and
3 days off carbimazole.
One year outcome without, on or 3 days off carbimazole
Overall, radioiodine treatment resulted in elimination of
biochemical hyperthyroidism in 71.5% (148/207) of all
patients: euthyroidism was achieved in 43.5% (90/207) and
hypothyroidism in 28.0% (58/207). Subgroup analysis
revealed that patients receiving radioiodine without carbi-
mazole showed a success rate of 81.4% (105/129; 95%
confidence interval 73.6–87.7%), while patients on carbi-
mazole had a success rate of 42.6% (23/54; 95%
confidence interval 29.2–56.8%; p<0.001). Patients in
whom carbimazole was withdrawn for 3 days had a success
rate of 83.3% (20/24; 95% confidence interval 62.6–
95.3%), which was significantly higher than the success
rate on carbimazole (p<0.0001) and comparable to the
success of radioiodine treatment without carbimazole
(p=0.82, Fig. 2a).
The pretherapeutic Crooks-Wayne scores of patients
without (median 7, range 0–28), on (median 8, range 0–26)
and 3 days off carbimazole (median 6, range 0–27) were
comparable (p=0.17, Table 1). In contrast, 12 months after
radioiodine treatment the Crooks-Wayne score was sig-
nificantly higher in patients on carbimazole (median 3,
range 0–30) than in patients without (median 0, range 0–
16) or 3 days off carbimazole (median 1, range 0–10)
(p=0.024, Fig. 2b).
Subgroup analysis of the biochemical outcome con-
firmed the overall results in patients suffering from toxic
nodular goitre as well as in patients suffering from Graves’
disease. In toxic nodular goitre patients (n=117), the 1-year
success rate on carbimazole (50.0%) was significantly
lower than that without carbimazole (86.4%, p<0.001) or
3 days off carbimazole (90.9%, p=0.025), while the
outcome without and 3 days off carbimazole was similar
(p=0.67, Fig. 3a). In patients suffering from Graves’
disease (n=90), the success rate was also significantly
lower in patients on carbimazole (38.9%) than in patients
without carbimazole (70.7%, p=0.005) or 3 days off
carbimazole (76.9%, p=0.019), whereas the success rates
without and 3 days off carbimazole were similar (p=0.66,
Fig. 3b).
Logistic regression analysis revealed that the unadjusted
odds ratio of a successful radioiodine therapy between
patients without and patients on carbimazole was 0.21
(95% confidence interval 0.10–0.41, p<0.0001). In con-
trast, the corresponding odds ratio comparing patients
without and patients 3 days off carbimazole was 1.39 (95%
confidence interval 0.44–4.4, p=0.58). The covariate-
adjusted odds ratio (adjusted for sex, age, thyroid volume,
radioiodine uptake, radioiodine half-life, fT4, T3, TSH,
Crooks-Wayne score and administered radioiodine dose,
respectively) of a successful radioiodine therapy compar-
ing patients without and patients on carbimazole was 0.13
(95% confidence interval 0.04–0.37, p<0.0001). In con-
trast, the corresponding odds ratio comparing patients
without and patients 3 days off carbimazole was 1.35 (95%
confidence interval 0.25–7.3, p=0.72).
Table 1. Baseline investigation results (n=207)
Off carbimazole On carbimazole 3 Days off carbimazole p value
(n=129) (n=54) (n=24)
Females (%) 85.3 72.2 79.2 n.s.
Age (years) 67 (25–90) 60 (25–83) 69 (28–87) n.s.
Goitre volume (ml) 27.2 (7.6–264.8) 34.5 (8.0–560.0) 25.8 (8.0–97.0) n.s.
Radioiodine uptake (%) 46.7 (31.0–88.8) 50.3 (30.0–92.6) 57.3 (32.8–81.2)a n.s.
Radioiodine half-life (days) 5.5 (0.6–7.9) 5.5 (0.8–7.4) 5.5 (2.1–6.8) n.s.
Crooks-Wayne score (points) 7 (0–28) 8 (0–26) 6 (0–27) n.s.
fT4 (pmol/l)b 22.9 (11.5–86.2) 15.4 (2.3–73.3) 18.7 (10.5–63.5) =0.001
T3 (nmol/l)b 2.5 (1.3–7.3) 2.3 (1.3–6.6) 2.2 (1.0–9.1) n.s.
TSH (mIU/l)b 0.03 (0.004–0.19) 0.08 (0.03–14.0) 0.03 (0.03–1.5) <0.001
Subclinical hyperthyroidism (%) 61.2 46.3 45.8 n.s.
Radioiodine activity (MBq)c 444 (185–814) 518 (259–1,295) 481 (222–925) n.s.
Values are expressed as median (range)
n.s. non-significant
aRadioiodine uptake values after 3 days of withdrawal of carbimazole
bReference ranges are: fT4, 9.0–24.5 pmol/l; fT3, 0.9–2.5 nmol/l; TSH, 0.25–4.0 mIU/l
cMegabequerels can be converted to microcuries by dividing by 37
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Radioiodine uptake and biochemical thyroid status
on and 3 days off carbimazole
In the group of patients receiving radioiodine 3 days off
carbimazole (n=24), radioiodine uptake levels were mea-
sured both on and off carbimazole. Thereby, the radioio-
dine uptake was found to increase significantly (p<0.001)
from a median of 14.9% (range 4.5–25.4%) on carbimazole
to a median of 57.3% (range 32.8–81.2%) 3 days off
carbimazole. Hence, the median increase in radioiodine
uptake was 3.8-fold (range 1.9–8.0 fold). On the other
hand, there was no significant change in the effective half-
life on carbimazole (median 5.3 days, range 0.8–7.3 days)
and 3 days off carbimazole (median 5.5 days, range 2.1–
6.8, p=0.12).
The biochemical thyroid status was also measured on
and off carbimazole in patients receiving radioiodine
3 days off carbimazole (n=24, Fig. 4a). There were no
significant differences between the levels of fT4
(median 18.7 pmol/l, range 10.5–63.5 pmol/l), T3 (median
2.2 nmol/l, range 1.0–9.1 nmol/l) and TSH (median
0.03 mIU/l, range 0.03–1.50 mIU/l) on carbimazole and
the levels of fT4 (median 17.7 pmol/l, range 9.7–42.8
pmol, p=0.27), T3 (median 2.4 nmol/l, range 1.3–4.4
nmol/l, p=0.48) and TSH (median 0.03 mIU/l, range 0.03–
1.17 mIU/l, p=0.49) 3 days off carbimazole. Additionally,
no patient suffered from clinical aggravation of hyperthy-
roidism as a result of the 3-day carbimazole withdrawal.
Time to achieve euthyroidism after radioiodine therapy
off, on or 3 days off carbimazole
Overall, hyperthyroidism was present in 45.6% of all
patients after 3 months, 32.0% after 6 months and 28.5%
after 12 months. At 3 months’ follow-up, hyperthyroidism
was present in 59.2% of patients who received radioiodine
on carbimazole as compared to 44.3% without carbimazole
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and 25.0% 3 days off carbimazole (p=0.02). Six months
after radioiodine treatment, hyperthyroidism was found in
52.4% of patients treated with radioiodine on carbimazole
as compared to 26.4% in patients treated without carbima-
zole and 20.8% in patients treated 3 days off carbimazole
(p=0.004, Fig. 4b).
Discussion
Based on our data, it can be asserted that simultaneous
carbimazole medication reduces the success of radioiodine
therapy in toxic nodular goitre and Graves’ disease inde-
pendently of the radioiodine uptake. Importantly, a 3-day
withdrawal is long enough to overcome this effect and to
restore the success of radioiodine treatment without the risk
of exacerbating hyperthyroidism. Furthermore, a 3-day
carbimazole withdrawal is able to reduce the time required
to achieve cure after radioiodine therapy as compared with
radioiodine treatment under carbimazole.
The cure rates of radioiodine therapy under adjuvant
thyrostatic medication have been investigated by previous
studies. However, most studies have merged patients on
diverse antithyroid drugs, namely thiamazoles and thioura-
cils, which have distinct detrimental effects on radioiodine
treatment [20]. The influence of carbimazole alone on
radioiodine treatment has been investigated in only a few
reports [3–8], in which low success rates of radioiodine
therapy with concomitant carbimazole treatment have
exclusively been associated with significantly lower
radioiodine uptake under carbimazole [3, 5]. Generally,
low radioiodine uptake is assumed to adversely affect the
success of radioiodine therapy [12, 13], although the
opposite effect has also been reported [16]. It is to be noted,
however, that in the above-mentioned reports, carbimazole
was identified as a confounder of radioiodine treatment
only in patient groups with incomparable baseline
characteristics due to differences in radioiodine uptake. In
other words, no studies have previously addressed the
question of whether carbimazole may exert an uptake-
independent detrimental effect on treatment outcome by
investigating groups with comparable radioiodine uptake.
To answer this question, our study protocol stratified
patients into groups with comparable radioiodine uptake.
We found that, despite similar uptake of the isotope,
patients on carbimazole had a significantly worse outcome
than patients who did not receive carbimazole. Thus,
simultaneous carbimazole medication was directly verified
to be an independent confounder of radioiodine treatment.
In addition, the low success rate of radioiodine therapy
under simultaneous carbimazole therapy in spite of
comparable radioiodine uptake strongly argues against a
radioiodine uptake-mediated detrimental mechanism of
carbimazole. In this context, radioprotection by the inhi-
bition of peroxidase-catalysed synthesis of oxygen free
radicals, which mediate the cell damage in radioiodine
therapy [10, 11], appears to be a more likely mechanism.
Anti-thyroid drugs are routinely used in the manage-
ment of both Graves’ disease and toxic nodular goitre [2,
21, 22]. There is controversy over whether their effect on
radioiodine treatment is similar in both diseases. Thiama-
zoles and thiouracils have been found to reduce the success
of radioiodine treatment in Graves’ disease [3, 5, 23–26].
In contrast, studies including both patients with Graves’
disease and patients with toxic nodular goitre revealed
propylthiouracil or multiple thyrostatics to have no effect in
Graves’ disease but an adverse influence in toxic nodular
goitre [21, 22]. However, the influence of simultaneous
carbimazole medication alone on radioiodine therapy in
toxic nodular goitre has not yet been investigated. The
present study included patients with Graves’ disease and
patients with toxic nodular goitre. The overall negative
effect of simultaneous carbimazole on radioiodine treat-
ment was confirmed to be similar in both subgroups.
Moreover, in contrast to previous reports, the negative
effect of carbimazole on radioiodine therapy was con-
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firmed not only biochemically but also clinically, as
quantified by the Crooks-Wayne score.
Previous reports have indicated that the success of
radioiodine treatment is not diminished if carbimazole is
discontinued for 16 days [6], 5 days [7] or 5 to 3 days [8]
before administration of radioiodine. However, even
merely 5 days of withdrawal can lead to aggravation of
hyperthyroidism [9], which is especially of concern in
patients with severe concomitant diseases. Our data
indicated that a 3-day withdrawal of carbimazole restored
the success of radioiodine therapy without an increase in
peripheral thyroid hormones or clinical aggravation of
hyperthyroidism. Nevertheless, this study did not have the
statistical power to proof non-inferiority regarding treat-
ment failure after 1 year.
Exacerbation of hyperthyroidism after radioiodine
therapy should also be avoided. Consequently, radioiodine
treatment is often performed under simultaneous carbima-
zole medication to prevent the increase in thyroid hormone
levels that is frequently observed in the first weeks after
radioiodine therapy without adjuvant thyrostatic medica-
tion [27]. However, contrary to this intended effect, the
present study revealed a significant delay in the return to
euthyroidism if radioiodine was performed under carbi-
mazole. Nevertheless, 3 days of carbimazole withdrawal
could overcome this effect.
Our study has limitations. The patient groups without,
on and 3 days off carbimazole were imbalanced with regard
to the number of patients. However, this imbalance is a
consequence of the study protocol, which had the primary
aim of generating groups with comparable radioiodine
uptake. Despite the limited number of patients receiving
radioiodine 3 days off carbimazole, we observed highly
significant detrimental effects of simultaneous carbimazole
therapy. One might also argue that a selection bias occurred
as a result of arranging groups according to their treatment
at the time of inclusion. However, in view of the similar
baseline characteristics of the three groups, this is unlikely
to have resulted in significant bias. Furthermore, if
randomisation is used to prevent a potential selection
bias, a systemic bias occurs owing to lower radioiodine
uptake in patients under carbimazole [3, 5]. Our therapy
results were derived from patients with radioiodine uptake
exceeding 30%. Further prospective interventional studies
would be helpful in clarifying the effect of carbimazole on
radioiodine treatment in patients with lower radioiodine
uptake.
In conclusion, patients under carbimazole treatment can
be referred for radioiodine therapy after withdrawal of
carbimazole for only 3 days. Three days of carbimazole
withdrawal is long enough to restore the success of
radioiodine therapy and short enough to avoid the risk of
exacerbation of hyperthyroidism.
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